Published by Benjamin Chiou on 16th May 2024
(Sharecast News) - Angle, the AIM-listed liquid biopsy company which specialises in circulating tumour cell (CTC) solutions, has announced the results of a clinical study which show that its Parsortix system could be used to predict progression-free survival in patients with ovarian cancer.
URL: http://www.digitallook.com/dl/news/story/34297484/...